12:00 AM
 | 
Feb 28, 2011
 |  BC Week In Review  |  Company News  |  Other News

Stallergenes, Ares Life Sciences inflammation news

Investment firm Ares re-opened its mandated offer in compliance with European law for the remaining stake of Stallergenes it does not own for €59 per share, or...

Read the full 115 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >